Tag Archive for: CYP11A1 inhibitor
UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxOST11098: A Promising New Approach for Castration-Resistant Prostate Cancer
/0 Comments/in Preclinical Research/by MaxPhase 1 Trial Will Soon Start Recruiting: ACE-232 a Promising Inhibitor of CYP11A1
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial of INV-9956: A Promising CYP11A1 Inhibitor Targeting Drug-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T castration-resistant prostate cancer clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA MYC nanotechnology neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- New Method Uses Nanoparticles to Create CAR T Cells Inside Body for Cancer Treatment June 23, 2025
- Newsletter 25/2025 June 22, 2025
- Phase 1 Trial for ART-101, a Novel Radioligand Targeting PSMA in mCRPC June 21, 2025
- Phase 1/2 For a New PARP1 Inhibitor: EIK1004 (IMP1707) For mCRPC June 20, 2025